| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Gambogic acid is a naturally occurring xanthonoid extracted from the resin of trees belonging to the Garcinia genus—most notably, Garcinia hanburyi. This tree is native to regions in Southeast Asia, particularly found in areas of China, India, and neighboring countries. Gambogic acid (GA; C38H44O8, MW: 628.76), a polyprenylated xanthone and a widely used coloring agent, is the main active ingredient of gamboges secreted from the Garcinia hanburyi tree ([3, 4], which mainly grows in Southeast Asia. GA has been approved by the Chinese FDA for the treatment of solid cancers in Phase II clinical trials. Pathways: -evidence suggesting that it can inhibit thioredoxin reductase (TrxR). -can indeed lead to an increase in reactive oxygen species (ROS) levels -Gambogic acid can trigger mitochondrial dysfunction, leading to cytochrome c release -influences death receptors -Inhibition of NF-κB Signaling -Inhibition of VEGF Pathway -Cell Cycle Arrest: -p53 Activation
|
| Source: HalifaxProj(inhibit) |
| Type: |
| Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport. Inhibitors: -Curcumin: downregulate AKT phosphorylation and signaling. -Resveratrol -Quercetin: inhibit the PI3K/AKT pathway. -Epigallocatechin Gallate (EGCG) -Luteolin and Apigenin: inhibit AKT phosphorylation |
| 5152- | GamB, | Gambogic Acid as a Candidate for Cancer Therapy: A Review |
| - | Review, | Var, | NA |
| 5151- | GamB, | Gambogic acid affects ESCC progression through regulation of PI3K/AKT/mTOR signal pathway |
| - | in-vitro, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE450 |
| 5148- | GamB, | Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics |
| - | Review, | Var, | NA |
| 1969- | GamB, | Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:302 Target#:4 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid